What the TGA’s 2026-2027 enforcement priorities mean for Australia’s 41 licensed cultivators and 27 manufacturers
Australia’s Therapeutic Goods Administration has drawn a line in the sand. In early 2026, the TGA released its new compliance principles for 2026-2027, and Australia TGA cannabis compliance 2025 standards are now under the most intense scrutiny since medicinal cannabis was legalized in 2016. With 41 licensed cultivators producing a record 41 tonnes in 2024, a market on pace to surpass AUD $1 billion in annual sales, and over 1,000 unapproved products circulating in the market, the regulator is shifting from reactive oversight to proactive, risk-based enforcement. For cannabis cultivators, manufacturers, and importers operating in or exporting to Australia, understanding these new Australia TGA cannabis compliance 2025 requirements is no longer optional—it is the cost of doing business.
Why the TGA Is Tightening Enforcement Now
Australia’s medicinal cannabis sector has grown at a pace that has outstripped the regulatory framework designed to govern it. Over 113,000 Special Access Scheme (SAS-B) applications were approved in the first half of 2025 alone—a 27% increase year-over-year—and the country is on track to surpass 200,000 total medical cannabis approvals by the end of the year. Flower-based products have overtaken oils as the most prescribed dosage form, and high-THC products are driving the bulk of new prescriptions.
This rapid expansion triggered a federal review of the TGA framework. Public consultation concluded in October 2025, with regulators scrutinizing product advertising, prescribing pathways, and quality oversight. The result: a new set of compliance principles that place medicinal cannabis alongside vapes, weight-loss drugs, and melatonin as priority enforcement areas for 2026-2027.
The TGA’s message is unambiguous. Cannabis is no longer a niche therapeutic product that can fly under the regulatory radar. Australia TGA cannabis compliance 2025 standards are now subject to quarterly reviews rather than annual assessments, giving the regulator the agility to respond to emerging quality threats in near real-time.
What the New Compliance Principles Require
TGO 93: The Quality Standard Every Operator Must Know
At the center of Australia TGA cannabis compliance 2025 is Therapeutic Goods Order 93 (TGO 93), the standard that governs testing, labelling, and manufacturing requirements for all medicinal cannabis products supplied in Australia. TGO 93 has been in effect for products released after July 1, 2023, but the TGA is now dramatically increasing the frequency and scope of its compliance audits.
Key TGO 93 requirements include:
- Active ingredient testing (Section 12): The concentration of cannabinoids in finished products must be measured, and the actual quantity must fall within a specified range of the stated quantity on the label.
- Contaminant screening: Products must be tested for toxins, heavy metals, pesticides, microbial contamination, and residual solvents. The TGA has flagged an increase in targeted testing for these contaminants.
- Labelling requirements (Section 15): Labels must include specific information for safe use, including cannabinoid content, dosage form, storage instructions, and—for plant material products—minimum dry or fresh weight.
- Child-resistant packaging: All medicinal cannabis products must use child-resistant closures.
- No synthetic cannabinoids: All cannabinoids in a product must be derived from the cannabis plant.
- No ethylene oxide: Ethylene oxide must not be used for decontamination, in line with international herbal medicine standards.
GMP Requirements: Cultivators vs. Manufacturers
The Australia TGA cannabis compliance 2025 framework draws a clear distinction between cultivators and manufacturers—and the obligations differ substantially.
| Obligation | Cultivators (40 licensed) | Manufacturers (25+ licensed) | Importers (35 licensed) |
|---|---|---|---|
| TGA Manufacturing Licence | Not required* | Required | Not required |
| GMP Compliance | Exempt (if material goes to GMP site) | Full compliance mandatory | Must hold evidence per batch |
| TGO 93 Compliance | Required | Required | Required |
| Random TGA Audits | Subject to audits | Subject to audits | Subject to audits |
| Batch-Level Documentation | Required for output | Required (full GMP records) | Required (GMP evidence per batch) |
*Cultivation sites that grow, cut, and dry cannabis plant material or perform a first crude extraction step are exempt from GMP, provided the material is transferred to a GMP-licensed site for further manufacture.
The Enforcement Teeth: Penalties and Recent Actions
The TGA is not issuing empty warnings. Recent enforcement actions demonstrate that Australia TGA cannabis compliance 2025 has real consequences for operators who fall short:
- Dispensed Pty Ltd: 6 infringement notices totalling $118,800 plus a direction notice for alleged unlawful advertising of medicinal cannabis.
- ACPharm Queensland Pty Ltd: 5 infringement notices totalling $99,000 for alleged unlawful advertising of therapeutic goods.
- Court proceedings: Cases commenced against Atlus and its sole director, as well as Mamamia, News Life, and Straight Up for advertising medicinal cannabis in alleged contravention of the Therapeutic Goods Act 1989.
These penalties apply to everyone in the supply chain—cultivators, manufacturers, sponsors, importers, and advertisers alike. The Therapeutic Goods Act 1989 provides for both criminal and civil court proceedings, which can result in substantial fines and imprisonment. Under the new quarterly review cycle, the TGA can escalate enforcement actions faster than ever. Operators who assume a warning letter is the end of the matter may find themselves facing court proceedings within months.
Who Is Most Affected
The 41 Licensed Cultivators
Australia’s 41 approved medicinal cannabis cultivators and producers face a paradoxical situation. Production has never been higher—41 tonnes in 2024, up from 25 tonnes the previous year and roughly 16-17 tonnes in 2021—but the compliance bar is rising just as fast. Cultivators who previously operated with minimal regulatory friction now face random TGO 93 audits, mandatory contaminant testing on output destined for supply, and labelling requirements that demand batch-level precision.
The 27 Licensed Manufacturers
Manufacturers bear the heaviest Australia TGA cannabis compliance 2025 burden. Full GMP compliance is mandatory, and the TGA is increasing the frequency of manufacturing site inspections. The January 2026 merger between Little Green Pharma and Cannatrek—creating a combined entity with USD $75.4 million in pro forma revenue and GMP-certified manufacturing in Australia and Denmark—signals that industry consolidation is being driven in part by the compliance cost of meeting these standards. Smaller manufacturers without the capital to maintain GMP certification may find themselves squeezed out.
International Operators and Importers
The 35 licensed importers face heightened scrutiny on overseas GMP documentation. The TGA’s January 2025 presentation on medicinal cannabis supply chains emphasized that sponsors must not only verify GMP compliance at the point of import, but maintain evidence that compliance was current at the time each batch was manufactured. For international operators looking to enter the Australian market, this means investing in supply chain documentation infrastructure before submitting a single product for approval.
What Operators Should Do Now
Compliance Checklist for 2026
- Audit TGO 93 compliance immediately. Review all product testing, labelling, and packaging against current TGO 93 requirements. Do not wait for a TGA audit to discover gaps.
- Verify GMP documentation. Manufacturers must ensure TGA manufacturing licences are current. Importers must hold batch-level GMP evidence for every product in the supply chain.
- Implement digital traceability. The TGA’s increased audit frequency makes manual record-keeping unsustainable. Operators need digital systems that can produce batch-level documentation, cannabinoid test results, and chain-of-custody records on demand.
- Review advertising and marketing materials. The TGA’s enforcement actions against advertising violations show this is a priority area. All promotional materials must comply with the Therapeutic Goods Act 1989.
- Monitor quarterly updates. Priority focus areas now receive quarterly reviews. Operators must designate compliance officers to track and respond to TGA updates in real time.
Operators who invest in cannabis compliance software with built-in regulatory tracking and automated documentation are better positioned to meet these demands without diverting operational resources. Similarly, implementing seed-to-sale tracking ensures that every batch of product can be traced from cultivation through manufacture to patient delivery—precisely the kind of documentation the TGA is now demanding.
Key Takeaways
- Highest enforcement priority: The TGA’s 2026-2027 compliance principles place medicinal cannabis among the top focus areas, with quarterly reviews replacing annual assessments.
- TGO 93 is non-negotiable: Every operator—cultivator, manufacturer, and importer—must meet TGO 93 standards covering active ingredient testing, contaminant screening, labelling, and child-resistant packaging.
- GMP distinctions matter: Cultivators are exempt from GMP if material goes to a GMP site, but manufacturers must hold TGA manufacturing licences. Importers need batch-level GMP evidence.
- Real penalties, real enforcement: Recent fines exceeding $100,000 and court proceedings show the TGA is actively enforcing compliance across the entire supply chain.
- $1 billion market at stake: Australia’s medicinal cannabis market is on pace to surpass AUD $1 billion in 2025, but operators who cannot demonstrate Australia TGA cannabis compliance 2025 standards risk losing their licence.
- Digital infrastructure is essential: The TGA’s audit frequency and documentation requirements make manual record-keeping unsustainable. Compliance management systems and seed-to-sale tracking are now operational necessities.
FAQ: Australia TGA Cannabis Compliance 2025
What is TGO 93 and why does it matter for cannabis operators?
Therapeutic Goods Order 93 (TGO 93) is the Australian standard that specifies minimum quality requirements for all medicinal cannabis products supplied in the country. It covers active ingredient testing, contaminant screening, labelling, packaging, and manufacturing standards. Compliance with TGO 93 is mandatory, and the TGA conducts random and targeted audits to verify adherence. Non-compliant operators face fines, direction notices, and potential court proceedings under the Therapeutic Goods Act 1989.
Do Australian cannabis cultivators need GMP certification?
Not necessarily. Cultivation sites that grow, cut, and dry cannabis plant material or perform a first crude extraction step are exempt from GMP certification, provided the material is transferred to a GMP-licensed site for further manufacture. However, cultivators must still comply with TGO 93 quality requirements and are subject to TGA compliance audits.
What penalties does the TGA impose for non-compliance?
The TGA has multiple enforcement tools, ranging from infringement notices (recent cases include fines of $99,000 and $118,800) to direction notices, court injunctions, and criminal or civil court proceedings. Penalties can include substantial fines and imprisonment. Critically, these offence provisions apply to every participant in the supply chain—cultivators, manufacturers, sponsors, and importers.
How many licensed cannabis operators are there in Australia?
As of February 2025, Australia has 41 approved medicinal cannabis cultivators and producers (40 allowed to cultivate and produce, 25 allowed to manufacture), 27 licensed product manufacturers, and 35 licensed importers. Licensed cultivators produced 41 tonnes in 2024, up from 25 tonnes the previous year.
What should international operators know about entering the Australian market?
International operators must ensure their manufacturing sites comply with GMP standards equivalent to those recognized by the TGA. Australian sponsors (importers) must hold evidence of GMP compliance that was valid at the time each batch was manufactured. The TGA’s 2025-2026 enforcement posture prioritizes supply chain integrity, making robust documentation and digital traceability essential for market entry.
Ready to Meet Australia’s TGA Compliance Standards?
See how GrowerIQ’s compliance platform helps cannabis producers meet TGO 93 requirements with automated documentation, batch-level traceability, and real-time regulatory tracking.
REQUEST DEMO About GrowerIQ
GrowerIQ is changing the way producers use software - transforming a regulatory requirement into a robust platform to learn, analyze, and improve performance.
To find out more about GrowerIQ and how we can help, fill out the form to the right, start a chat, or contact us.